Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort

Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort

Abstract Introduction Dolutegravir (DTG)-based antiretroviral therapy (ART) is currently the first-line treatment for people living with HIV. Neuropsychiatric adverse events (NP-AEs) have been reported with DTG but neuropsychiatric symptoms have not been systemically quantified using structured scal...

Full description

Bibliographic Details
Main Authors: Phillip Chan, Orlanda Goh, Eugène Kroon, Donn Colby, Carlo Sacdalan, Suteeraporn Pinyakorn, Peeriya Prueksakaew, Peter Reiss, Jintanat Ananworanich, Victor Valcour, Serena Spudich, Robert Paul, the RV254/SEARCH 010 Research Team
Format: Article
Language:English
Published: BMC 2020-01-01
Series:AIDS Research and Therapy
Subjects:
Dolutegravir
Neuropsychiatric adverse events
Depression
RV254
Cognitive performance
Online Access:https://doi.org/10.1186/s12981-019-0257-8

Internet

https://doi.org/10.1186/s12981-019-0257-8

Similar Items